INS068 injection

DRUG5 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Diabetes MellitusType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects

CompletedNCT05336071

Jiangsu HengRui Medicine Co., Ltd.Diabetes Mellitus

Start: 2022-05-12End: 2022-06-02Updated: 2023-06-08

Phase 2

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

CompletedNCT04663282

Jiangsu HengRui Medicine Co., Ltd.Type 2 Diabetes

Start: 2021-02-04End: 2022-05-28Updated: 2022-12-21

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

Jiangsu HengRui Medicine Co., Ltd.Type 2 Diabetes

Start: 2022-07-08End: 2024-03-30Updated: 2023-04-25

Phase 3

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

CompletedNCT05699408

Jiangsu HengRui Medicine Co., Ltd.Type 2 Diabetes

Start: 2023-03-31End: 2024-11-23Updated: 2025-02-18

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

CompletedNCT05702073

Jiangsu HengRui Medicine Co., Ltd.Type 2 Diabetes Mellitus

Start: 2023-03-31End: 2024-06-11Updated: 2025-03-13

Related Papers

Pharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study

Frontiers in Pharmacology2023-12-222 citations